| Name | Title | Contact Details |
|---|
Evexia Diagnostics provides comprehensive, cutting-edge, clinical laboratory services at unbeatable prices with a focus on the Functional Medicine and Integrative Medicine, cash-based practice.
Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the cancer continuum. With a leading portfolio of products for earlier detection and treatment guidance, we help people face the most challenging decisions with confidence. Our dedication to taking on the impossible fuels everything we do. We are continuously innovating, combining scientific rigor with an open-minded approach to deliver the next big thing. We are Exact Sciences, and we`re changing lives together through earlier detection and smarter answers.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.
Botanacor Laboratories was founded in 2014 and leads the U.S. in third-party testing for hemp products. The company is committed to providing consistent and accurate hemp testing services to ensure its customers meet regulatory compliance and industry safety demands. By following cGMP and GLP requirements in an ISO 17025 accredited laboratory, and by working intensively to validate its facilities, equipment, and processes, Botanacor remains the first choice in testing throughout the hemp supply chain.
Suncoast Clinical Laboratories is a Ocala, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.